Cagrilintide

Published · Researched 2026-09-21

1. Overview

• Maker: Novo Nordisk. Development code NNC0113-2023.
• Purpose: Long-acting amylin analogue — the amylin half of Novo Nordisk's CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg once-weekly) program. In trials it is delivered only as part of the fixed-dose CagriSema combination; gray-market vendors sell cagrilintide as a standalone research peptide, sometimes community-stacked with a GLP-1.
• Current 2026 version: Investigational. REDEFINE Phase 3 complete (data published NEJM June 2025); Novo planned regulatory submission in H1 2026 (per Spherix/GlobeNewswire, Dec 2025). Not approved or marketed as of Sept 2026. Gray-market: 5 mg / 10 mg lyophilized vials, research use only.

2. Social standing

• Platform pulse: Strong pipeline-watch buzz, weak firsthand-use signal. CagriSema (and cagrilintide by extension) is a fixture of "next-generation peptide" ranking content, but actual owner/user discussion is thin — nearly all of it is about trial results and market implications, not personal experience.
• Facebook group consensus: No posts mentioning cagrilintide found in the two public peptide Facebook groups searched via facebook-cli (Sept 2026).
• Viral moments: None observed for cagrilintide itself; REDEFINE 1 results (June 2025) generated broad investor/creator commentary.
• Praise: Threads @sky._.grove (Dec 2024): reported the CagriSema 68-week trial "show improvement over previous semaglutide (Wegovy)," noting ~22.7% weight reduction figure in circulation. Threads @berry.matcha26 (Aug 2026): "Hallu, CagriSema tu apa ye?" (Malay: "what is CagriSema?") — 8 replies, showing retail-community curiosity about the combo in SE Asia. Medium reviewer james-b (Jun 2026): frames CagriSema as the "next breakthrough" worth weighing against compounded semaglutide now ($300/month) vs. waiting for "22.7% average weight loss."
• Complaints: Tolerability/dosing: ainvest.com (June 2025) notes only 57.3% of REDEFINE 1 participants reached the highest dose, raising questions about tolerability and flexible dosing; GI side effects common. The FormBlends TikTok breakdown (via formblends.com): flags real chemistry concern — cagrilintide's fibrillation risk and formulation incompatibility (dual-chamber device design), warns against "research blends" mixed from separate powders, noting such blends are not FDA-reviewed products. james-b (Medium, Jun 2026): cautions that as of mid-2026 CagriSema "is not FDA-approved for weight management in the U.S." and won't be compoundable initially — projected brand pricing $1,300–$1,400/month without insurance.
• Verified quotes (paraphrased, attributed):
  • Threads @berry.matcha26 (Aug 2026): asked "what is CagriSema?" in Malay, sparking 8 replies — platform: Threads (shows grassroots awareness).
  • Threads @dr.purplehwi (Feb 2026, Korean-language): reported REDEFINE-4 results — CagriSema ~23% weight loss at 84 weeks vs. tirzepatide 15 mg ~25.5%, failing to prove non-inferiority — platform: Threads (investor/physician commentary layer).
  • glp1.app explainer: "CagriSema sold online, mixed from separate powders, or described as a research blend is not an FDA-reviewed product. There is no approved U.S. label to copy." — platform: web (glp1.app).
  • Threads @sky._.grove (Dec 2024): discussed the trial readout context — platform: Threads.

3. Social validation — Tier 3 (weak)

• Tier 3 — flagged as weak. Real user/owner voices exist only on Threads (4 identifiable Threads users discussing CagriSema/cagrilintide across Dec 2024–Aug 2026). No Facebook Groups presence, no IG owner content, and no firsthand user experience reports — discussion is pipeline/trial-focused.
• Named sources and what each proves:
  1. Threads @berry.matcha26 (Aug 2026, 8 replies) — proves grassroots retail awareness/curiosity in SE Asia; user-generated discussion.
  2. Threads @sky._.grove (Dec 2024) — proves trial-watch interest among peptide followers.
  3. Threads @dr.purplehwi (Feb 2026) — proves investor/physician commentary layer around REDEFINE-4; not user experience.
  4. Threads @dr.alla_zaentc ranking post — proves cagrilintide appears in creator "next-gen" peptide rankings; matches on keyword only (post covers other peptides in caption shown).
  5. FormBlends TikTok breakdown (via formblends.com) — proves creator scrutiny of gray-market "research blends" as non-FDA-reviewed.
  6. Searched but empty: Facebook group post queries (Sept 2026), IG owner content.

4. Key specs table

5. Pricing (dated 2026-09-20)

• Current MSRP (brand): None — not approved; no official price. Medium reviewer james-b (Jun 2026) projects brand pricing at $1,300–$1,400/month without insurance when launched — estimate, not official.
• Street price (research/compounded): PeptidePub catalog snapshot (Sept 3, 2026, via Medium): 12 cagrilintide listings across 5 mg and 10 mg; after-code normalized $5.95–$37.43/mg (strongest examples: Double R 10 mg at $59.49; Ascension 10 mg at $60; AMP 10 mg at $79.20). Observed retail listings: ezpeptides.com 5 mg at $44.00 (crawl 2026-09-18); Amino USA 10 mg at $102.00 (listed; page last updated Feb 2026 — likely stale); Prime Lab Peptides 10 mg at $150.00; Pure Peptide Labs 5/10 mg from $59.95 (listed sold out).
• Marketplace used range: None observed.

6. What is included / what else is needed

• Brand: N/A — no product; trial form is a dual-chamber device (formblends.com notes the design reflects formulation incompatibilities between cagrilintide and semaglutide).
• Gray-market: Lyophilized powder vial — bacteriostatic water, insulin syringes, alcohol swabs required. Research chemical not for human use. Safety note: cagrilintide has documented fibrillation (misfolding/aggregation) risk; community "research blends" of cagrilintide + semaglutide from separate powders are not FDA-reviewed and replicate none of Novo's formulation engineering.

7. Support reality

• Brand: N/A — investigational.
• Gray-market: Vendor-dependent; some vendors advertise money-back guarantees and third-party COAs (e.g., Amino USA) — treat vendor marketing as such. Purity claims (≥99%) unverified by independent testing.

8. Community verdict

Cagrilintide lives in the peptide world's future tense: it is one of the most discussed amylin-pathway compounds, almost entirely through CagriSema trial readouts and rankings rather than anyone's own vial. The informed layer is cautiously optimistic about REDEFINE data (highest efficacy reported in any Phase 3, prediabetes reversion of 88%) but frank that gray-market standalone use lacks the formulation engineering that makes the trial product work — mixing research powders is not the same drug, and the chemistry doesn't forgive it.

9. Regulatory & safety status

• Investigational drug — NOT FDA/EMA approved as a standalone drug or as CagriSema. Any vial sold online is an unapproved research chemical not for human use. Compounded or "research blend" versions are not FDA-reviewed products.
• Known safety signals (trials): GI adverse events in 79.6% of CagriSema participants (vs 39.9% placebo) in REDEFINE 1 — mostly transient; discontinuation due to AEs 6–8.4%. Only 57.3% of REDEFINE 1 participants reached the highest dose, raising tolerability questions (ainvest.com, Jun 2025). Amylin fibrillation/misfolding is a documented formulation risk (formblends.com) — a real-world handling concern for non-pharma vials.

10. Missing-image views + UNVERIFIED points log

• Images found (2/8): hero (ARL 10 mg research vial product photo, sanantoniopeptides.com), side (Novatide Peptides 10 mg product photo, novatidepeptide.com). Retailer product photography; no owner photos. Rejected: PTLabs render (misspelled "CAGRILINTINTIDE" label — clearly AI-generated). Missing: rear, top, detail, owner-in-use, scale, box/accessories.
• UNVERIFIED:
  1. Exact half-life and molecular details.
  2. Brand MSRP — no official price exists; $1,300–$1,400/month is a reviewer's projection (Medium, Jun 2026).
  3. Vendor price listing freshness — Amino USA $102 page last updated Feb 2026; likely stale.
  4. Vendor purity claims (≥99%, COAs) — marketing, not independently verified.
  5. Facebook Marketplace used range — not observed.
  6. Novo submission timeline (H1 2026 per Dec 2025 Spherix piece) — no later confirmation fetched.

Not medical advice. This is research material only; consult a qualified clinician.

Named sources

• Threads @berry.matcha26 (Aug 2026, 8 replies) — proves grassroots retail awareness/curiosity in SE Asia (Aug 2026)
• Threads @sky._.grove (Dec 2024) — proves trial-watch interest among peptide followers. (Dec 2024)
• Threads @dr.purplehwi (Feb 2026) — proves investor/physician commentary layer around REDEFINE-4 (Feb 2026)
• Threads @dr.alla_zaentc ranking post — proves cagrilintide appears in creator "next-gen" peptide rankings
• FormBlends TikTok breakdown (via formblends.com) — proves creator scrutiny of gray-market "research blends" as non-FDA-reviewed.
• acc.org — Measured efficacy: REDEFINE 1 (68 wks, non-diabetic obesity, n=3,417): CagriSema 20.4% ITT (22.7% on-treatment) vs semaglutide alone 14.9%, cagrilintide alone 11.5%, placebo 3.0%; ~60% ≥20% loss, 40.4% ≥25% loss; 88% prediabetes reversion. (Jun 22, 2025)
• NEJM — Dosing schedule: REDEFINE 1/2: once-weekly subcutaneous CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg), flexible titration; cagrilintide-only phase 2 used weekly dosing (Jun 22, 2025)
• Lancet 2021 phase 2 — Dosing schedule: REDEFINE 1/2: once-weekly subcutaneous CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg), flexible titration; cagrilintide-only phase 2 used weekly dosing (Jun 22, 2025)
• formblends.com — Administration route: Subcutaneous injection (dual-chamber device in trials); gray-market standalone is reconstituted powder
• NEJM Jun 2025 — Trial phase: Phase 3 complete (REDEFINE 1/2/4); regulatory submission planned H1 2026 (per Dec 2025 Spherix piece). (Jun 2025)
• financialcontent.com Dec 2025 — Trial phase: Phase 3 complete (REDEFINE 1/2/4); regulatory submission planned H1 2026 (per Dec 2025 Spherix piece). (Jun 2025)
• NEJM (Garvey — Measured efficacy: REDEFINE 1 (68 wks, non-diabetic obesity, n=3,417): CagriSema 20.4% ITT (22.7% on-treatment) vs semaglutide alone 14.9%, cagrilintide alone 11.5%, placebo 3.0%; ~60% ≥20% loss, 40.4% ≥25% loss; 88% prediabetes reversion. (Jun 22, 2025)
• Davies, Jun 22, 2025) — Measured efficacy: REDEFINE 1 (68 wks, non-diabetic obesity, n=3,417): CagriSema 20.4% ITT (22.7% on-treatment) vs semaglutide alone 14.9%, cagrilintide alone 11.5%, placebo 3.0%; ~60% ≥20% loss, 40.4% ≥25% loss; 88% prediabetes reversion. (Jun 22, 2025)
• SE Asia. Medium review — Threads @berry.matcha26 (Aug 2026): "Hallu, CagriSema tu apa ye?" (Malay: "what is CagriSema?") — 8 replies, showing retail-community curiosity about the combo in SE Asia. (Aug 2026)
• Medium review — Medium reviewer james-b (Jun 2026) projects brand pricing at $1,300–$1,400/month without insurance when launched — estimate, not official. (Jun 2026)
• Spherix — Dec 2025 Spherix piece: regulatory submission planned H1 2026 (Dec 2025)
• GlobeNewswire — - **Current 2026 version:** Investigational. (June 2025)
• Medium — - **Street price (research/compounded):** PeptidePub catalog snapshot (Sept 3, 2026, via Medium): 12 cagrilintide listings across 5 mg and 10 mg; after-code normalized… (2026-09-18)

Source URLs were not recorded for these references.